M
0.416
-0.60 (-59.20%)
| Previous Close | 1.02 |
| Open | 0.880 |
| Volume | 18,259,823 |
| Avg. Volume (3M) | 554,006 |
| Market Cap | 2,940,453 |
| Price / Book | 0.470 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -4.99 |
| Total Debt/Equity (MRQ) | 1,071.43% |
| Current Ratio (MRQ) | 1.35 |
| Operating Cash Flow (TTM) | -21.71 M |
| Levered Free Cash Flow (TTM) | -12.26 M |
| Return on Assets (TTM) | -62.45% |
| Return on Equity (TTM) | -214.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Moleculin Biotech, Inc. | Mixed | Bullish |
AIStockmoo Score
-0.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 6.13% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |